How effective is ivonib in the treatment of acute myeloid leukemia?

Ivosidenib is a targeted drug specifically used to treat acute myeloid leukemia (AML) carrying IDH1 gene mutations. IDH1Mutation leads to the excessive accumulation of abnormal metabolite 2-hydroxyglutarate (2-HG), thereby interfering with the normal cell differentiation process and promoting the proliferation of cancer cells. Ivonib inhibits the activity of IDH1 mutant enzyme and reduces the production of 2-HG, thereby restoring the normal blood cell production process. This mechanism makes ivonib an effective tool for treating certain types of AML. The following is a detailed introduction to the clinical effects of ivonib in the treatment of AML.

Clinical trial data

1. AG120-C-001Test

AG120-C-001is a pivotal clinical trial evaluating the efficacy and safety of ivonib in patients with IDH1 mutated acute myeloid leukemia. This is a multicenter, open-label, single-arm Phase II clinical trial designed to determine the efficacy of ivonib in patients with advanced or relapsed/refractory AML.

Experimental design and methods:

Subjects: The trial included147IDH1 mutatedAML patients. Most of these patients have received at least two treatment options, including chemotherapy and/or hematopoietic stem cell transplantation, but their disease has not been effectively controlled.

Dose: Patients take 500 mg of ivonib orally daily and continue treatment until disease progression or unacceptable toxicity.

Primary endpoint: objective response rate (ORR), including complete response (CR) and partial response (PR).

Results:

Objective response rate: Among 147 patients, 24% achieved complete response (CR), and 8% of patients achieved partial response (PR), and the overall ORR was 32%. This indicates that ivonib has significant efficacy in patients with AML mutations in IDH1.

Median progression-free survival (PFS): The median PFS is 8.2 months, showing that the drug can effectively control disease progression.

Median overall survival (OS): The median OS is 17.8 months, indicating that ivonib can not only control the disease, but also significantly extend the survival of patients.

2. AG120-C-004Test

The AG120-C-004 trial is an expansion phase II clinical trial that further evaluates the safety and efficacy of ivonib in patients with IDH1 mutated AML.

Experimental design and methods:

Subjects: The trial enrolled 73IDH1mutated advanced or relapsedAML patients. Patients in the trial were treated with 500mg of ivonib daily.

Primary endpoints: including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

Results:

Objective response rate: In this trial, the ORR of ivonib was 34%, showing that the drug was IDH1 Efficacy in patients with mutatedAML was slightly higher than in the AG120-C-001 trial.

Disease control rate:DCR is 60%, which means that the drug can stabilize disease progression in most patients.

Median progression-free survival (PFS): The median PFS is 5.7 months, which is consistent with the AG120-C-001 trial results.

Median overall survival (OS): The median OS is 11.3 months, further verifying the role of ivonib in prolonging patient survival.

Safety of ivonib

The safety of ivonib has been evaluated in multiple clinical trials and results indicate that adverse effects are generally manageable. Common adverse reactions include:

1.Hematological toxicity: such as leukopenia, anemia and thrombocytopenia. These side effects usually require regular monitoring of hematological parameters and adjustment of treatment plans according to the situation.

2.Gastrointestinal effects: such as nausea, vomiting, diarrhea, and loss of appetite, can usually be managed with symptomatic treatment.

3.QTinterval prolongation: Ivonib may cause QT interval prolongation, which requires regular ECG monitoring.

A small number of patients may experience more serious side effects such as differentiation syndrome (although this is less common in AML), and patients with similar symptoms need immediate medical attention.

Overall, ivonib has significant clinical effects in the treatment of IDH1mutated AML patients, providing new hope for the treatment of this specific population. With the deepening of research, the application of ivonib may be further expanded, bringing good news to more AML patients.